Labcorp最高8.72亿美元收购OPKO旗下BioReference剩余检测资产，OPKO盘前涨约25%

Labcorp ( LH ) has inked a deal worth up to $872M to acquire a portfolio of assets held by BioReference Health LLC, a subsidiary of OPKO Health ( OPK ), the companies announced on Thursday. OPKO ( OPK ) shares added more than 20% in the premarket after the announcement, while Labcorp ( LH ) traded flat. Under the agreement, BioReference Health's laboratory testing businesses focused on clinical and women's health testing services, urology, corrections, and certain operational assets will be part of Labcorp ( LH ), a North Carolina-based lab testing services provider. The deal also includes BioReference Health's patient service centers, numbering more than 80, and its 4Kscore Test, an FDA-approved blood-based test used for the detection of prostate cancer. Per the terms, Labcorp ( LH ) is expected to pay $722M in cash upfront for the purchase, adjusted for an upward or downward revision to account for the target business’s revenues at the closing. The purchase price includes an additional earnout worth up to $150M based on revenue from BioReference Health's 4Kscore Test. Labcorp ( LH ) forecasts the assets under consideration to generate roughly $250M in revenue during the first year after closing.